Trial reportJournal of neural transmission (Vienna, Austria : 1996)2008
Effect of copper intake on CSF parameters in patients with mild Alzheimer's disease: a pilot phase 2 clinical trial.
Trial report in Journal of neural transmission (Vienna, Austria : 1996), 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 62 citations in OpenAlex.
- Essential and non-essential metals in children's intellectual functioning: A multi-media biomarker approach from a Mexico City birth cohort.Environmental research · 2025Article
- Does Nutritional Supplementation Have a Disease-Modifying Effect on the Alzheimer's Disease Neurodegenerative Process?JAR life · 2024Review
- Metals in Alzheimer's Disease.Biomedicines · 2023Review
- Re-evaluation of the existing health-based guidance values for copper and exposure assessment from all sources.EFSA journal. European Food Safety Authority · 2023Article
- Article
- Heavy Metals and Essential Metals Are Associated with Cerebrospinal Fluid Biomarkers of Alzheimer's Disease.International journal of molecular sciences · 2022Article
- Brain copper may protect from cognitive decline and Alzheimer's disease pathology: a community-based study.Molecular psychiatry · 2022Article
- Preventive and Therapeutic Strategies in Alzheimer's Disease: Focus on Oxidative Stress, Redox Metals, and Ferroptosis.Antioxidants & redox signaling · 2021Review
- Effect of Human Immunodeficiency Virus on Trace Elements in the Brain.Biological trace element research · 2021Article
- Imbalances in Copper or Zinc Concentrations Trigger Further Trace Metal Dyshomeostasis in Amyloid-Beta ProducingFrontiers in neuroscience · 2021Article
- Copper Dyshomeostasis in Neurodegenerative Diseases-Therapeutic Implications.International journal of molecular sciences · 2020Review
- The Effect of the Human Peptide GHK on Gene Expression Relevant to Nervous System Function and Cognitive Decline.Brain sciences · 2017Article
- Role of Copper in the Onset of Alzheimer's Disease Compared to Other Metals.Frontiers in aging neuroscience · 2017Review
- Effects of a copper-deficient diet on the biochemistry, neural morphology and behavior of aged mice.PloS one · 2012Article
- The human tripeptide GHK-Cu in prevention of oxidative stress and degenerative conditions of aging: implications for cognitive health.Oxidative medicine and cellular longevity · 2012Review
- Cholesterol increases ventricular volume in a rabbit model of Alzheimer's disease.Journal of Alzheimer's disease : JAD · 2012Article
- Disturbed copper bioavailability in Alzheimer's disease.International journal of Alzheimer's disease · 2011Article
- Copper modulation as a therapy for Alzheimer's disease?International journal of Alzheimer's disease · 2011Article
- Gene-environment interaction research and transgenic mouse models of Alzheimer's disease.International journal of Alzheimer's disease · 2010Article
- Copper in the brain and Alzheimer's disease.Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A plethora of reports suggest that copper (Cu) homeostasis is disturbed in Alzheimer's disease (AD). In the present report we evaluated the efficacy of oral Cu supplementation on CSF biomarkers for AD. In a prospective, randomized, double-blind, placebo-controlled phase 2 clinical trial (12 months long) patients with mild AD received either Cu-(II)-orotate-dihydrate (verum group; 8 mg Cu daily) or placebo (placebo group). The primary outcome measures in CSF were Abeta42, Tau and Phospho-Tau. The clinical trial demonstrates that long-term oral intake of 8 mg Cu can be excluded as a risk factor for AD based on CSF biomarker analysis. Cu intake had no effect on the progression of Tau and Phospho-Tau levels in CSF. While Abeta42 levels declined by 30% in the placebo group (P = 0.001), they decreased only by 10% (P = 0.04) in the verum group. Since decreased CSF Abeta42 is a diagnostic marker for AD, this observation may indicate that Cu treatment had a positive effect on a relevant AD biomarker. Using mini-mental state examination (MMSE) and Alzheimer disease assessment scale-cognitive subscale (ADAS-cog) we have previously demonstrated that there are no Cu treatment effects on cognitive performance, however. Finally, CSF Abeta42 levels declined significantly in both groups within 12 months supporting the notion that CSF Abeta42 may be valid not only for diagnostic but also for prognostic purposes in AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.